A more traditional COVID vaccine is on the way. Some can’t wait.

“Some people can’t take the mRNA vaccines, and it is important to have a choice,” said Victoria Dawson, 74, of New York, who is allergic to an ingredient in the mRNA shots. She received a Johnson & Johnson shot and booster but hopes her next shot will be from Novavax. “I’m being very cautious. I’m staying around my apartment complex and not eating in restaurants,” she said. “I get up in the morning and just stress the minute I get up.”

Advertisement

Even though Novavax lost the race to be first, company executives argue that their shot will help fill in the margins of the pandemic vaccination campaign and play an important role in helping people live alongside the virus into the future. They argue their vaccine, which can stay stable at refrigerator temperatures longer and may be better tolerated than alternatives, will have key advantages once the exigencies of the pandemic recede.

But hopes were dashed Friday that the vaccine would offer an alternative for people worried about rare heart inflammation associated with mRNA vaccines. An FDA review found that there were five cases of inflammation, mostly in men, within two weeks of being vaccinated in Novavax trials, “raising concern for a causal relationship.”

Join the conversation as a VIP Member

Trending on HotAir Videos

Sponsored

Advertisement
Advertisement
Advertisement